Arena Pharmaceuticals, Inc. (ARNA) Reaches $39.94 After 3.00% Down Move; Last Week Newpark Resources, Inc. (NR) Coverage

February 15, 2018 - By Linda Rogers

The stock of Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) is a huge mover today! The stock decreased 2.55% or $1.04 during the last trading session, reaching $39.94. About 227,117 shares traded. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) has declined 11.92% since February 15, 2017 and is downtrending. It has underperformed by 28.62% the S&P500.The move comes after 6 months negative chart setup for the $1.57 billion company. It was reported on Feb, 15 by Barchart.com. We have $38.74 PT which if reached, will make NASDAQ:ARNA worth $47.04M less.

Among 6 analysts covering Newpark Resources (NYSE:NR), 5 have Buy rating, 0 Sell and 1 Hold. Therefore 83% are positive. Newpark Resources had 13 analyst reports since September 4, 2015 according to SRatingsIntel. The rating was upgraded by Loop Capital on Thursday, January 5 to “Buy”. Tudor Pickering upgraded the stock to “Buy” rating in Monday, May 2 report. The rating was maintained by Cowen & Co on Tuesday, February 16 with “Outperform”. Cowen & Co maintained the shares of NR in report on Thursday, January 11 with “Hold” rating. The firm earned “Outperform” rating on Wednesday, June 1 by Credit Suisse. Credit Suisse reinitiated Newpark Resources, Inc. (NYSE:NR) rating on Monday, July 18. Credit Suisse has “Outperform” rating and $7 target. Cowen & Co maintained the shares of NR in report on Friday, July 7 with “Hold” rating. The company was maintained on Friday, September 4 by Credit Suisse. The stock of Newpark Resources, Inc. (NYSE:NR) has “Buy” rating given on Thursday, November 2 by SunTrust. The stock of Newpark Resources, Inc. (NYSE:NR) has “Hold” rating given on Friday, October 6 by Cowen & Co. See Newpark Resources, Inc. (NYSE:NR) latest ratings:

11/01/2018 Broker: Cowen & Co Rating: Hold New Target: $10.0 Maintain
02/11/2017 Broker: SunTrust Old Rating: Hold New Rating: Buy Upgrade
06/10/2017 Broker: Cowen & Co Rating: Hold New Target: $9.0 Maintain

Arena Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing novel small molecule drugs for various therapeutic areas in the United States and Switzerland. The company has market cap of $1.57 billion. The companyÂ’s proprietary investigational clinical programs include etrasimod , which is in Phase IIb evaluation for ulcerative colitis, as well as is in Phase IIa evaluation for dermatologic extraintestinal manifestations in inflammatory bowel disease, pyoderma gangrenosum, and primary biliary cholangitis; ralinepag that is in Phase IIb evaluation to treat pulmonary arterial hypertension; and APD371, which is in Phase IIa evaluation for the treatment of pain associated with Crohn's disease. It currently has negative earnings. It has collaboration agreements with Eisai Inc.; Eisai Co., Ltd.; Axovant Sciences Ltd.; and Boehringer Ingelheim International GmbH.

Analysts await Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) to report earnings on March, 13. They expect $-0.64 earnings per share, down 140.00% or $2.24 from last year’s $1.6 per share. After $-0.65 actual earnings per share reported by Arena Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -1.54% EPS growth.

Among 8 analysts covering Arena Pharmaceuticals (NASDAQ:ARNA), 6 have Buy rating, 0 Sell and 2 Hold. Therefore 75% are positive. Arena Pharmaceuticals had 16 analyst reports since October 28, 2015 according to SRatingsIntel. As per Tuesday, August 8, the company rating was maintained by Needham. As per Wednesday, October 28, the company rating was maintained by WallachBeth Capital. Citigroup maintained the shares of ARNA in report on Wednesday, July 12 with “Buy” rating. The firm has “Outperform” rating by FBR Capital given on Thursday, September 15. Cantor Fitzgerald maintained the stock with “Buy” rating in Tuesday, July 11 report. The stock has “Buy” rating by Leerink Swann on Monday, July 17. The firm has “Buy” rating given on Wednesday, November 8 by Cantor Fitzgerald. Cantor Fitzgerald maintained Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) rating on Wednesday, July 19. Cantor Fitzgerald has “Buy” rating and $3700 target. The stock of Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) has “Buy” rating given on Thursday, January 4 by Cantor Fitzgerald. As per Thursday, June 29, the company rating was maintained by Cantor Fitzgerald.

Investors sentiment decreased to 0.97 in Q3 2017. Its down 0.17, from 1.14 in 2017Q2. It turned negative, as 18 investors sold Newpark Resources, Inc. shares while 57 reduced holdings. 28 funds opened positions while 45 raised stakes. 87.91 million shares or 0.11% more from 87.81 million shares in 2017Q2 were reported. Alliancebernstein Lp invested 0% in Newpark Resources, Inc. (NYSE:NR). Louisiana State Employees Retirement Sys invested in 0.02% or 34,700 shares. Epoch Inv Partners Incorporated holds 1.88 million shares. Eam Limited Com invested in 0.26% or 195,125 shares. Los Angeles Cap Mngmt Equity Incorporated reported 32,510 shares or 0% of all its holdings. 4,259 were reported by Pnc Fin Group Inc. Advsr Asset Management holds 0% or 11,704 shares in its portfolio. Deutsche Bank Ag has invested 0% of its portfolio in Newpark Resources, Inc. (NYSE:NR). Mason Street Advsrs Ltd Llc holds 0.01% or 21,682 shares in its portfolio. Goldman Sachs holds 0% of its portfolio in Newpark Resources, Inc. (NYSE:NR) for 829,800 shares. Citigroup Inc invested in 334 shares or 0% of the stock. Arizona State Retirement System invested in 0.01% or 44,371 shares. Falcon Point Capital Ltd Llc holds 0.15% or 119,774 shares. Teachers Retirement Of The State Of Kentucky reported 22,900 shares stake. Miles invested in 25,864 shares.

Newpark Resources, Inc., together with its subsidiaries, provides services and products primarily to the gas and oil exploration and production industry. The company has market cap of $735.94 million. The firm operates through two divisions, Fluids Systems and Mats and Integrated Services. It currently has negative earnings. The Fluids Systems segment offers drilling fluids products and technical services for technical drilling projects involving complex subsurface conditions, including horizontal, directional, geologically deep, or deep water drilling.

The stock decreased 0.60% or $0.05 during the last trading session, reaching $8.25. About 416,433 shares traded or 3.59% up from the average. Newpark Resources, Inc. (NYSE:NR) has risen 85.19% since February 15, 2017 and is uptrending. It has outperformed by 68.49% the S&P500.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


>